Immunome Inc.
IMNM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001472012
In the last 90 days, Immunome Inc. insiders filed 0 open-market purchases and 7 sales; 202 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Immunome Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 30 | 29 | −1 |
| Shares | 2.79M | 2.69M | −96.5K (−3.5%) |
| Value | $36.4M | $15.4M | −$20.9M (−57.6%) |
New holders (3)
Institutions that held Immunome Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Baldwin Investment Management, LLC | 25,394 | $144.0K | 0.04% |
| First Republic Investment Management, Inc. | 15,270 | $87.0K | 0.00% |
| Renaissance Technologies LLC | 14,000 | $80.0K | 0.00% |
Sold out (4)
Institutions that held Immunome Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Citadel Advisors LLC | 21,216 | $275.0K |
| Marshall Wace, LLP | 10,654 | $138.0K |
| Bank of America Corp | 6,244 | $81.0K |
| Simplex Trading, LLC | 6,086 | $78.0K |